NCNE | Adult Psychiatric Medication Management & Telehealth

  1. Home
  2. Insights
  3. Can a Psychiatric Nurse Practitioner Prescribe ADHD Medication in Connecticut, Massachusetts, and Other New England States?

Can a Psychiatric Nurse Practitioner Prescribe ADHD Medication in Connecticut, Massachusetts, and Other New England States?

September 23, 2026

Psychiatric nurse practitioners can prescribe ADHD medications, including Schedule II stimulants, in all seven states where NCNE provides care — Connecticut, Massachusetts, New Hampshire, Maine, Rhode Island, Virginia, and Kentucky — but the level of oversight varies. Five of these states grant full practice authority, which means psychiatric-mental health nurse practitioners evaluate, diagnose, and prescribe independently without physician supervision, while Virginia and Kentucky require a practice agreement with a physician that specifies what controlled substances the nurse practitioner may prescribe.

If you are seeking ADHD evaluation and medication management by telehealth in any of these states, understanding how your state regulates nurse practitioner prescribing helps you know what to expect when you schedule care.

What does full practice authority mean for ADHD medication?

Full practice authority means a psychiatric nurse practitioner can evaluate patients, order diagnostic tests, diagnose ADHD, and prescribe stimulants and non-stimulant medications without a physician's signature, collaborative agreement, or supervisory oversight. The nurse practitioner operates under the exclusive authority of the state board of nursing, holds their own DEA registration for controlled substances, and makes independent clinical decisions within their scope of training.

For adult patients seeking ADHD care, this means you can see a psychiatric nurse practitioner as your sole prescriber — no separate psychiatrist or physician is involved unless the PMHNP refers you for something outside psychiatric medication management.

As of 2026, approximately 30 states and Washington, D.C., grant full practice authority to nurse practitioners, up from 22 in 2020, and five of the seven states NCNE serves are among them.

Connecticut: Full practice authority after three years

Connecticut grants full practice authority to psychiatric nurse practitioners, but new APRNs must practice under a collaborative agreement with a physician for their first three years. The agreement must be in writing and must specifically address the level of Schedule II and III controlled substances that the APRN may prescribe, which means ADHD stimulants are explicitly part of the scope discussion during that initial period.

After maintaining licensure for at least three years and completing 2,000 hours of advanced practice nursing in collaboration with a physician, a Connecticut PMHNP may notify the Department of Public Health and transition to independent practice. At that point, no collaborative agreement is required, and the nurse practitioner prescribes Schedule II stimulants and other ADHD medications independently.

For patients, this means a newly licensed PMHNP in Connecticut works with physician oversight for the first three years, and an experienced PMHNP prescribes independently — the clinical training and the prescribing authority are the same either way.

Massachusetts: Full practice authority with updated Schedule II rules

Massachusetts is a full practice authority state, and psychiatric nurse practitioners with independent prescriptive authority evaluate and prescribe ADHD medications without a practice agreement. Massachusetts recently updated its Schedule II prescribing rules to allow 90-day supplies for non-opioid Schedule II medications such as stimulants, and the state no longer requires verification of ADD or ADHD diagnoses for stimulant prescriptions.

Nurse practitioners who require supervision of their prescriptive practice must ensure their supervisor's name appears on each prescription, but psychiatric-mental health nurse practitioners who have met the state's requirements for independent practice authority are not subject to that rule.

New Hampshire, Maine, and Rhode Island: Full practice authority

New Hampshire, Maine, and Rhode Island are all full practice authority states where psychiatric nurse practitioners evaluate, diagnose, and prescribe ADHD medications independently. Rhode Island has provided NPs with full autonomy since 2008, and New Hampshire grants full autonomy and even provides temporary licenses to newly graduated nurse practitioners who have not yet completed the national certification exam.

In these three states, a PMHNP operates with the same prescribing authority as a psychiatrist for Schedule II stimulants and all other ADHD medications, and no collaborative agreement or physician oversight is required at any stage of practice.

Virginia: Restricted practice with a practice agreement

Virginia requires psychiatric nurse practitioners to work under a written or electronic practice agreement with a physician, and the agreement must clearly state which Schedule II through Schedule IV controlled substances the nurse practitioner is authorized to prescribe. Under Virginia Code § 54.1-2957.01, a PMHNP practicing under a practice agreement may prescribe Schedule II through Schedule VI controlled substances, but the specific drugs — including ADHD stimulants — must be listed in the agreement or the nurse practitioner may not prescribe them.

The practice agreement does not need to be filed with the Virginia Board of Nursing or Board of Medicine, and both the nurse practitioner and the physician maintain copies. For psychiatric-mental health nurse practitioners specifically, Virginia allows one physician to serve as the patient care team physician for up to 10 PMHNPs at a time, recognizing the specialized nature of psychiatric prescribing.

For patients in Virginia, this means your psychiatric nurse practitioner is authorized to prescribe ADHD medications and manages your care directly, but a physician practice agreement is part of the legal framework behind the scenes.

Kentucky: Reduced practice with collaborative agreement for controlled substances

Kentucky requires psychiatric nurse practitioners to establish a collaborative agreement for prescriptive authority for controlled substances (CAPA-CS) with a physician who holds an active and unrestricted Kentucky license in a same or similar specialty. The nurse practitioner must notify the Kentucky Board of Nursing of the agreement, upload proof of DEA registration, and provide evidence of access to the state's prescription drug monitoring program (KASPER).

During the first year of practice, Kentucky APRNs must meet with their collaborating physician at least quarterly to review prescription monitoring data, and the meetings — which may occur in person or by videoconference — must be documented in writing. After the first year, meetings occur biannually for three additional years.

After four or more years of continuous controlled substance prescribing in good standing, a Kentucky APRN may request exemption from the CAPA-CS requirement, which effectively transitions the nurse practitioner to a more independent practice model for Schedule II prescribing.

For adults seeking ADHD care in Kentucky, a psychiatric nurse practitioner prescribes stimulants and manages treatment under a physician collaborative agreement, with the structure becoming less restrictive as the nurse practitioner gains experience in the state.

What is Schedule II and why does it matter?

ADHD stimulants — amphetamine-based medications such as Adderall, Vyvanse, and Dexedrine, and methylphenidate-based medications such as Ritalin, Concerta, and Focalin — are classified as Schedule II controlled substances under the federal Controlled Substances Act. Schedule II drugs are recognized as having accepted medical use but also carry high potential for abuse and dependence, which is why their prescribing is more tightly regulated than non-controlled medications.

Any prescriber who writes prescriptions for Schedule II controlled substances, whether a psychiatrist, physician, or nurse practitioner, must hold a federal DEA registration number and complete the MATE Act training requirement — at least eight hours of one-time education on treating and managing patients with opioid or other substance use disorders, attested at the first registration or renewal on or after June 27, 2023.

The DEA registration and training requirements are the same for psychiatric nurse practitioners and psychiatrists, and both are subject to the same federal telehealth rules for prescribing controlled substances, which currently allow Schedule II stimulants to be prescribed via video visit without an initial in-person evaluation under a temporary extension running through December 31, 2026.

State law determines whether a nurse practitioner must work under a practice agreement to prescribe Schedule II medications, but federal law sets the baseline training and registration requirements for all prescribers.

Does clinical training differ between psychiatrists and psychiatric nurse practitioners for ADHD care?

No. Psychiatric-mental health nurse practitioners complete graduate-level clinical training in psychopharmacology, psychiatric diagnosis, and controlled substance prescribing that covers the same medications and the same clinical decision-making as psychiatric residency training. The curriculum includes stimulants, non-stimulants, antidepressants used off-label for ADHD, and the evaluation process for distinguishing ADHD from conditions that can present similarly, such as anxiety, depression, sleep disorders, and trauma.

The difference is not what a PMHNP knows how to prescribe — it is whether state law requires a practice agreement or allows independent prescribing. A review of psychiatric-mental health nurse practitioner care published in PMC found that broader scopes of practice are associated with improved service accessibility and workforce stability without compromising quality or safety, and that patient satisfaction with PMHNP-led care is high.

For adults seeking ADHD medication management, the evaluation process, the diagnostic questions, the medication options, and the follow-up monitoring are the same whether the prescriber holds an MD, DO, or PMHNP credential.

How does this apply to telehealth ADHD care?

State licensure rules apply the same way by telehealth as they do in person: the psychiatric nurse practitioner must be licensed in the state where you are physically located during the video visit, and the practice authority rules of that state determine whether the PMHNP prescribes independently or under a practice agreement.

A PMHNP licensed in Connecticut and Massachusetts who provides telehealth care to patients in both states prescribes independently in both, because both are full practice authority states. The same PMHNP providing care to a patient in Virginia must hold a Virginia license and work under a Virginia practice agreement that specifies Schedule II prescribing authority.

Federal telehealth flexibilities for controlled substances, extended most recently through December 31, 2026, allow psychiatric nurse practitioners and psychiatrists to prescribe ADHD stimulants via video visit without requiring an initial in-person evaluation, but those flexibilities are temporary and may change after the current extension expires. For current federal telehealth rules and how they interact with state prescribing laws, see our earlier post on whether a psychiatric nurse practitioner can prescribe ADHD medication.

What matters for someone seeking ADHD evaluation and medication management

If you are located in Connecticut, Massachusetts, New Hampshire, Maine, Rhode Island, Virginia, or Kentucky and you are considering ADHD evaluation by telehealth, here is what the state-by-state prescribing rules mean in practical terms:

  • A psychiatric nurse practitioner in any of these states can evaluate you for ADHD and prescribe stimulants and non-stimulant medications if clinically appropriate. The prescribing authority exists in all seven states, whether the nurse practitioner works independently or under a practice agreement.
  • You will not be asked to see a separate physician for a prescription. Even in Virginia and Kentucky, where a practice agreement is required, the PMHNP manages your care and writes your prescriptions — the collaborative agreement is a regulatory structure, not a clinical barrier.
  • The evaluation process is the same. A comprehensive ADHD evaluation covers current symptoms, how long they have been present, how they affect work or relationships, past treatments, medical history, sleep, mood, substances, and what you have already tried — the same questions and the same diagnostic process whether the state calls the arrangement full practice authority or restricted practice.
  • Follow-up care happens with the same prescriber. Medication management for ADHD requires regular follow-up to monitor effectiveness, adjust doses, watch for side effects, and coordinate with any therapy or other care you are receiving, and a psychiatric nurse practitioner provides that ongoing care in all seven states.

The legal structure varies by state, but the clinical care does not.

ADHD medication management at NCNE

NCNE provides psychiatric medication management for adults aged 18 to 65 by telehealth in Connecticut, Massachusetts, New Hampshire, Maine, Rhode Island, Virginia, and Kentucky. ADHD evaluation and treatment is part of that work — a 60-minute initial psychiatric evaluation to clarify symptoms, rule out other conditions that can look like ADHD, review what has already been tried, and build an individualized plan, followed by regular medication management visits to adjust doses, monitor response, and coordinate with your therapist or primary care provider as needed.

NCNE's psychiatric nurse practitioner is licensed in all seven states and holds DEA registration for Schedule II prescribing, which means stimulant and non-stimulant ADHD medications are both within scope where clinically appropriate. Initial evaluations are typically $250–$350 before insurance, and follow-up visits are typically $125–$200 before insurance — in-network with most major plans, and superbills are available for possible out-of-network reimbursement where plans allow it.

If you are located in any of the seven states NCNE serves and you are seeking ADHD evaluation or medication management, you can send a message and someone will respond within two business days, or review insurance and fees first to understand what your plan covers.

If you are in immediate danger, call 911. For urgent support at any hour, call or text 988 (Suicide & Crisis Lifeline). This article is general information, not medical advice. Never start, stop, or change a prescribed medication without speaking to your prescriber first.

References

Considering psychiatric care?

Laura Gabriel, PMHNP-BC, NCNE's board-certified psychiatric nurse practitioner, provides adult psychiatric evaluations and medication management by secure video across Connecticut, Massachusetts, New Hampshire, Maine, Rhode Island, Virginia, and Kentucky, and is currently accepting new clients.

What to expectSend a message